Wafik S. El-Deiry: Dr. Vivek Subbiah presents on AI’s impact in oncology research at AACR Grantee Summit

Wafik S. El-Deiry posted the following on LinkedIn:

“Dr. Vivek Subbiah gives a fantastic presentation about the clinical relevance of AI in oncology practice and clinical research at the American Association for Cancer Research Grantee Summit.

He spoke about multimodal data fusions and that AI will reduce the costs of science and drug development in oncology. Recognizing patterns permeates many medical disciplines. He mentioned that AI is able to recognize ~20% more tumors that are susceptible to immunotherapy.

Transformative impact in pathology, radiology and data processing are enabled by AI.

See Swanton et al in Cell 2024.

Dr. Subbiah’s vision is that AI can drastically reduce the time of drug development from several years (5–10 years or more) to much less (2–3 years). He spoke about ethical and regulatory challenges, as well as issues with access to drugs.”

Embracing cancer complexity: Hallmarks of systemic disease

Authors: Charles Swanton, Elsa Bernard, Chris Abbosh, Fabrice André, Johan Auwerx, Allan Balmain, Dafna Bar-Sagi, René Bernards, Susan Bullman, James DeGregori, Catherine Elliott, Ayelet Erez, Gerard Evan, Mark A. Febbraio, Andrés Hidalgo, Mariam Jamal-Hanjani, Johanna A. Joyce, Matthew Kaiser, Katja Lamia, Jason W. Locasale, Sherene Loi, Ilaria Malanchi, Miriam Merad, Kathryn Musgrave, Ketan J. Patel, Sergio Quezada, Jennifer A. Wargo, Ashani Weeraratna, Eileen White, Frank Winkler, John N. Wood, Karen H. Vousden, Douglas Hanahan

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center   Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.